

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

CHANGE OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that, with effect from 7 June 2024, (1) Mr. Hou Bo has resigned as a non-executive Director of the Company; and (2) Mr. Guo Chuan has been appointed as a non-executive Director of the Company.

RETIREMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that, with effect from 7 June 2024, Mr. Hou Bo (“**Mr. Hou**”) has resigned as a non-executive Director as he has reached his retirement age. Mr. Hou has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the holders of securities of the Company.

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Hou for his invaluable contributions to the Company and the Board.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that, with effect from 7 June 2024, Mr. Guo Chuan (“**Mr. Guo**”) has been appointed as a non-executive Director.

Mr. Guo Chuan, aged 56, has been appointed as a non-executive Director on 7 June 2024. Mr. Guo has joined Beijing State-owned Capital Operation and Management Company Limited (“**BSCOMC**”) since January 2024, and is currently the deputy party committee secretary, director and general manager of BSCOMC. From 1997 to 2024, he held various positions at Beijing North Star Company Limited (the shares of which are listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (stock code: 588) and on the Shanghai Stock Exchange (stock code: 601588)), including serving as the director of the secretariat of the board of directors, secretary to the board of directors, chief legal advisor and deputy general manager, and as an executive director from May 2018 to January 2024. Mr. Guo graduated from the Capital University of Economics and Business with a bachelor’s degree in economic law, and the University of International Business and Economics with an EMBA degree, and is a qualified lawyer.

There is no service contract entered into between Mr. Guo and the Company for his position as a non-executive Director. Mr. Guo shall hold office until the next annual general meeting of the Company after his appointment and shall then be eligible for re-election at such meeting. Thereafter, Mr. Guo shall be subject to retirement by rotation at least once every three years at the annual general meeting pursuant to the articles of association of the Company. Mr. Guo will not receive any Director’s emolument from the Company.

Pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”), as at the date of this announcement, Mr. Guo does not have any interest in the shares of the Company and its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, Mr. Guo have confirmed that (i) he has and had no other relationships with any Directors, senior management or substantial or controlling shareholders of the Company; (ii) he does not currently hold any other position with the Company or any of its subsidiaries; (iii) he has not held any directorship in other Hong Kong or overseas listed public companies in the last three years; (iv) there are no other matters relating to the aforesaid appointment that need to be brought to the attention of holders of securities of the Company; and (v) there is no other information relating to the aforesaid appointment to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board takes this opportunity to extend a warm welcome to Mr. Guo for the appointment.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 7 June 2024

As at the date of this announcement and after the aforesaid changes, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.